ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

Stock Information for ProQR Therapeutics N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProQR Therapeutics N.V.

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
ProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meeting
ProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfolio
ProQR Announces Year End 2023 Operating and Financial Results
ProQR Announces Japanese Axiomer(TM) Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
ProQR Highlights New Platform Data from Presentation on Axiomer(TM) RNA Editing Technology at Deaminet 2024
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer(TM) RNA Editing Collaboration
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.